ZYMEWORKS WKN: A3DSSN ISIN: US98985Y1082 Forum: Aktien User: Summer.76

https://www.sec.gov/Archives/edgar/data/1937653/000092189523000006/0000921895-23-000006-index.htm

https://newsfilter.io/a/26ed65126e6bf06a7bb0f61edec86e59 Form SC 13G (statement of acquisition of beneficial ownership by individuals) filed with the SEC

https://www.prnewswire.com/news-releases/jazz-pharmaceuticals-and-zymeworks-announce-jazz-has-confirmed-opt-in-and-advances-partnership-for-zanidatamab-301707906.html

Jazz Pharmaceuticals and Zymeworks Announce Jazz has Confirmed Opt-in and Advances Partnership for Zanidatamab

Benzinga's Top Ratings Upgrades, Downgrades For December 20, 2022 https://www.benzinga.com/analyst-ratings/upgrades/22/12/30146428/benzingas-top-ratings-upgrades-downgrades-for-december-20-2022 Upgrades ... According to Jefferies, the prior rating for Zymeworks BC Inc (NYSE:ZYME) was changed from Hold to Buy. In the third quarter, Zymeworks BC showed an EPS of $0.66, compared to $1.25 from the year-ago quarter. The current stock performance of Zymeworks BC shows a 52-week-high of $17.27 and a 52-week-low of $4.11. Moreover, at the end of the last trading period, the closing price was at $6.79. ...

Zymeworks Announces Positive Topline Data in the Pivotal HERIZON-BTC-01 Trial of Zanidatamab https://www.businesswire.com/news/home/20221219005219/en/Zymeworks-Announces-Positive-Topline-Data-in-the-Pivotal-HERIZON-BTC-01-Trial-of-Zanidatamab • Zanidatamab as monotherapy produced a confirmed objective response rate (cORR) of 41.3% and median duration of response of 12.9 months in patients with previously treated HER2-amplified and expressing biliary tract cancers (BTC) • Pending receipt of regulatory approvals, zanidatamab has the potential to be the first HER2-targeted therapy for patients with BTC

🎈

⬆️

Zanidatamab Clinical Data Selected For Presentation At The American Society Of Clinical Oncology (ASCO) Gastrointestinal Cancers Symposium https://www.businesswire.com/news/home/20221214005989/en/Zanidatamab-Clinical-Data-Selected-For-Presentation-At-The-American-Society-Of-Clinical-Oncology-ASCO-Gastrointestinal-Cancers-Symposium ...today announced the upcoming presentation of mature Phase 2 data evaluating zanidatamab in combination with chemotherapy as first-line treatment for HER2-positive gastroesophageal adenocarcinoma (GEA) at the ASCO Gastrointestinal Cancers Symposium, taking place in San Francisco, CA and virtually on January 19-21, 2023. ....

https://ir.zymeworks.com/news-releases/news-release-details/new-clinical-data-zanidatamab-her2-hr-metastatic-breast-cancer-0

...The company expects that its common stock (together with the associated preferred stock purchase rights) will cease trading on the NYSE at market close on December 15, 2022. The company expects its common stock (together with the associated preferred stock purchase rights) to commence trading on the Nasdaq on December 16, 2022, and will continue to be listed under the ticker symbol "ZYME".

https://ir.zymeworks.com/news-releases/news-release-details/zymeworks-transfer-stock-listing-nasdaq Zymeworks To Transfer Stock Listing To Nasdaq

Zymeworks Announces Expiration of Hart-Scott-Rodino Waiting Period for Zanidatamab License Agreement with Jazz Pharmaceuticals https://www.businesswire.com/news/home/20221129005175/en/Zymeworks-Announces-Expiration-of-Hart-Scott-Rodino-Waiting-Period-for-Zanidatamab-License-Agreement-with-Jazz-Pharmaceuticals

https://ir.zymeworks.com/news-releases/news-release-details/zymeworks-announces-participation-upcoming-investor-conference-0

Zymeworks Announces Abstract For Zanidatamab In Late-Line HER2-Positive Hormone-Receptor Positive (HR+) Metastatic Breast Cancer At The San Antonio Breast Cancer Symposium (SABCS) https://www.businesswire.com/news/home/20221121005239/en/Zymeworks-Announces-Abstract-For-Zanidatamab-In-Late-Line-HER2-Positive-Hormone-Receptor-Positive-HR-Metastatic-Breast-Cancer-At-The-San-Antonio-Breast-Cancer-Symposium-SABCS ...A poster with an updated and expanded data set will be presented at SABCS taking place in San Antonio, Texas and virtually on December 6-9, 2022. ...

Zymeworks Non-GAAP EPS of -$0.66 beats by $0.31, revenue of $2.6M misses by $1.95M https://seekingalpha.com/news/3904028-zymeworks-non-gaap-eps-of-0_66-beats-0_31-revenue-of-2_6m-misses-1_95m • Zymeworks press release (NYSE:ZYME): Q3 Non-GAAP EPS of -$0.66 beats by $0.31. • Revenue of $2.6M (-40.9% Y/Y) misses by $1.95M.